No abstract

Cancer Research UK, Medical Research Council.

The optimum treatment of nonresectable low-grade gliomas of childhood remains undecided. There has been increased interest in the use of chemotherapy for young children, but little information concerning the long-term efficacy of such treatment. Seventy-eight children with a mean age of 3 years (range 3 months-16 years) who had newly diagnosed, progressive low-grade gliomas were treated with combined carboplatin and vincristine chemotherapy. The patients were followed for a median of 30 months from diagnosis, with 31 patients followed for more than 3 years. Fifty-eight children had diencephalic tumors, 12 had brainstem gliomas, and three had diffuse leptomeningeal gliomas. Forty-four (56%) of 78 patients showed an objective response to treatment. Progression-free survival rates were 75 +/- 6% at 2 years and 68 +/- 7% at 3 years. There was no statistical difference in progression-free survival rates between children with neurofibromatosis Type 1 and those without the disease (2-year, progression-free survival 79 +/- 11% vs. 75 +/- 6%, respectively). The histological subtype of the tumor, its location, and its maximum response to chemotherapy did not have an impact on the duration of disease control. The only significant prognostic factor was age: children 5 years old or younger at the time of treatment had a 3-year progression-free survival rate of 74 +/- 7% compared with a rate of 39 +/- 21% in older children (p < 0.01). Treatment with carboplatin and vincristine is effective, especially in younger children, in controlling newly diagnosed progressive low-grade gliomas.

The authors retrospectively reviewed 117 pediatric patients with posterior fossa tumors treated at The Children's Hospital and Medical Center, Seattle, Washington, between 1976 and 1990, in an attempt to determine what perioperative and intraoperative factors influenced the need for postoperative shunts. The ages of the patient population ranged from 4 months to 16 years 9 months. The factors evaluated included age at diagnosis, duration of symptoms, extent of hydrocephalus, tumor location, extent of tumor resection, presence and duration of an external ventricular drain, flow of cerebrospinal fluid (CSF) through the fourth ventricle after tumor resection, presence of hemostatic cavity linings, method of dural closure, tumor type, CSF infection, CSF leak, and pseudomeningocele formation. Of these variables, young age at diagnosis, tumors affecting midline structures, subtotal tumor resection as determined by immediate postoperative scans, prolonged requirement of an external ventricular drain, cadaveric dural grafts, pseudomeningocele formation, and CSF infections were statistically significant factors associated with the need for postoperative shunt placement, which was required in 36% of all patients. Therefore, considering the pertinent factors that may influence the need for postoperative shunt placement, a radical tumor resection should be done when possible, especially for midline lesions, and closure of the operative wound should be meticulous to avoid a CSF leak and subsequent infection. Foreign body dural substitutes as a cause of an inflammatory response in the CSF should also be avoided. Persistence of a pseudomeningocele despite serial taps and time will eventually require placement of a shunt after posterior fossa tumor surgery.